STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more

The FDA has flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug. Argenx faces an unusual setback in its clinical trial for an obesity drug, and Eli Lilly faces lawsuits over copycat versions of its obesity drug.